FOLD vs. ARWR, BHVN, BHC, PRGO, TPTX, EXAS, RGEN, EXEL, HALO, and IONS
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Arrowhead Pharmaceuticals (ARWR), Biohaven (BHVN), Bausch Health Companies (BHC), Perrigo (PRGO), Turning Point Therapeutics (TPTX), Exact Sciences (EXAS), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.
Arrowhead Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.
In the previous week, Arrowhead Pharmaceuticals had 3 more articles in the media than Amicus Therapeutics. MarketBeat recorded 9 mentions for Arrowhead Pharmaceuticals and 6 mentions for Amicus Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.25 beat Amicus Therapeutics' score of 0.76 indicating that Amicus Therapeutics is being referred to more favorably in the news media.
Amicus Therapeutics has a net margin of -34.73% compared to Amicus Therapeutics' net margin of -163.32%. Arrowhead Pharmaceuticals' return on equity of -77.08% beat Amicus Therapeutics' return on equity.
Amicus Therapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Arrowhead Pharmaceuticals currently has a consensus price target of $50.00, indicating a potential upside of 117.86%. Amicus Therapeutics has a consensus price target of $17.57, indicating a potential upside of 79.30%. Given Amicus Therapeutics' higher probable upside, research analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Amicus Therapeutics.
Arrowhead Pharmaceuticals received 7 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 73.54% of users gave Amicus Therapeutics an outperform vote while only 65.26% of users gave Arrowhead Pharmaceuticals an outperform vote.
62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Amicus Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
